<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01804361</url>
  </required_header>
  <id_info>
    <org_study_id>UMT-2012-DH-HS-01</org_study_id>
    <secondary_id>1360-8040-3073-4190</secondary_id>
    <nct_id>NCT01804361</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes</brief_title>
  <official_title>Efficacy and Safety Study of Haporine-S in Subjects With Moderate to Severe Dry Eye, A Multicenter, Investigator(Assessor)Blind, Parallel Design, Non-inferiority Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DH Bio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BTO Pharm Co Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DH Bio Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy and safety of Haporine-S eye drop for the
      patients with moderate to severe dry eye disease in a multicenter phase III clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the efficacy and the safety of topical Haposine-S and RestasisÂ® eye
      drop 0.05% for the patients with moderate to severe dry eye disease in a multicenter,
      investigator(assessor) blind, parallel design, non-inferiority phase III trial.

      Primary outcome is the change of corneal staining score(Oxford scheme) at 12 weeks from
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Corneal staining</measure>
    <time_frame>up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal fluorescein staining will be assessed at 0 day(baseline), 4 weeks and 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index(OSID)</measure>
    <time_frame>0 day, 4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ocular Surface Disease Index(OSID) will be assessed at 0 day, 4 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Breakup Time(TBUT)</measure>
    <time_frame>0 day, 4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tear Breakup Time(TBUT) will be assessed at 0 day(baseline), 4 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer score</measure>
    <time_frame>0 day, 4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Schirmer score will be assessed at 0 day(baseline), 4 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>0 day, 4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug compliance(conjunctival hyperemia and burning etc) will be assessed at 0 day(baseline), 4 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEWS(Dry Eye WorkShop) level</measure>
    <time_frame>0 day, 4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Level on dry eye severity grading scheme of DEWS will be assessed at 0 day(baseline), 4 weeks and 12 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Event will be assessed for the whole study period(1 year).</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serious Adverse Event will be assessed for the whole study period(1 year).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Haporine-S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate to severe dry patients administered with with Haporine-S</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis, Cyclosporine 0.05%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haporine-S</intervention_name>
    <description>1 or 2 drops twice a day at 12 hour interval for 12 weeks</description>
    <arm_group_label>Haporine-S</arm_group_label>
    <other_name>Haporine-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis (cyclosporine 0.05%)</intervention_name>
    <description>1 or 2 drops twice a day at 12 hour interval for 12 weeks</description>
    <arm_group_label>Restasis, Cyclosporine 0.05%</arm_group_label>
    <other_name>Restasis (cyclosporine 0.05%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 20 or over

          -  Patients with moderate to severe dry eye(DEWS Level II or over)

          -  Be informed of the nature of the study and will give written informed consent

        Exclusion Criteria:

          -  Being treated with steroidal eye drop or non-steroidal anti-inflammatory eye drop for
             dry eye

          -  Being treated with systemic steroid or immunosuppressive

          -  History of eyeball surgical operation within 6 months

          -  Wearing contact lenses during participation of the study

          -  Pregnancy or breastfeeding

          -  Use of cyclosporine eye drop within 2 weeks

          -  Intraocular pressure(IOP)&gt; 25 mmHg

          -  History of punctal occlusion within 1 month or during participation of the study

          -  Hypersensitivity to the investigational products or be suspicious to them

          -  Patients whom the investigator considers inappropriate to participate in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Myung KIM, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Suk SONG, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyung Keun LEE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong-Soo LEE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mee Kum KIM, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myoung-Joon KIM, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Myung Kim, MD, PhD</last_name>
    <phone>+82-2-920-5776</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Busan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Soo LEE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jong-Soo LEE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Myung KIM, MD, PhD</last_name>
      <phone>+82-2-920-5776</phone>
    </contact>
    <investigator>
      <last_name>Hyo-Myung KIM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Suk SONG, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jong Suk SONG, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myoung-Joon KIM, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Myoung-Joon KIM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mee Kum KIM, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mee Kum KIM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Keun LEE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hyung Keun LEE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 30, 2013</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Syndromes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
